|

Trastuzumab emtansine (T-DM1) Clinical Trials

2 actively recruiting trials

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • The First Affiliated Hospital with Nanjing Medical University1
  • Shanghai JMT-Bio Inc.1

Indications

  • Breast Cancer2
  • Cancer2
  • Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants1
  • Trastuzumab Emtansine1
  • Objective Response Rate1

Other2 trials

JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
Phase 3
Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.